Back
Speaker illustration

Mr Jin Yang

Tenaya Therapeutics, South San Francisco (United States of America)

Member of:

Heart Failure Association

Presentations

HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction

Event: Heart Failure 2022

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart Failure ePosters - focus on Chronic Heart Failure 5

Access
Like
Thumbnail

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Event: Heart Failure 2021

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 1

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources